Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Clin Cancer Res
    November 2024
  1. GREEN AK, Zhou Q, Iasonos A, Zammarrelli WA, et al
    A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
    Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999.
    >> Share

    October 2024
  2. BRAVO MELGAR J, Laoui D
    Chemotherapy Sparks Tertiary Lymphoid Structures in Metastatic Ovarian Cancer.
    Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-24-2738.
    >> Share

  3. CHAE YK, Othus M, Patel SP, Wilkinson KJ, et al
    SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-0606.
    >> Share

  4. SOBERANIS PINA P, Clemens K, Bubie A, Grant B, et al
    Genomic landscape of circulating tumor DNA and real-world outcomes in advanced endometrial cancer.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-2105.
    >> Share

    September 2024
  5. JEON SH, You G, Park J, Chung Y, et al
    Anti-4-1BBxPDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
    Clin Cancer Res. 2024;30:4155-4166.
    >> Share

  6. JOHANNET P, Friedman CF
    The intrauterine device: how to deploy this strategy in the molecular world?
    Clin Cancer Res. 2024 Sep 10. doi: 10.1158/1078-0432.CCR-24-2034.
    >> Share

    August 2024
  7. LANICKOVA T, Hensler M, Kasikova L, Vosahlikova S, et al
    Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.
    Clin Cancer Res. 2024 Aug 20. doi: 10.1158/1078-0432.CCR-24-1594.
    >> Share

  8. MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al
    Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.
    Clin Cancer Res. 2024;30:3640.
    >> Share

  9. BLANC-DURAND F, Ngoi NYL, Lim DG, Tan DSP, et al
    Unveiling Commonalities: Exploring Shared Characteristics in Clear Cell Carcinomas of the Gynecologic Tract.
    Clin Cancer Res. 2024 Aug 14. doi: 10.1158/1078-0432.CCR-24-1205.
    >> Share

    July 2024
  10. RICHARDSON DL, Quintanilha JCF, Danziger N, Li G, et al
    Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice.
    Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-1225.
    >> Share

  11. BONFILL-TEIXIDOR E, Neva-Alejo A, Arias A, Cuartas I, et al
    Cervical Cancer Evades the Host Immune System Through the Inhibition of Type I Interferon and CXCL9 by LIF.
    Clin Cancer Res. 2024 Jul 30. doi: 10.1158/1078-0432.CCR-24-0385.
    >> Share

  12. CORTES JE, Abruzzese E, Cardonick EH, Hernandez-Diaz S, et al
    Perspectives on drug development for the treatment of chronic myeloid leukemia in pregnant patients and patients who are breastfeeding.
    Clin Cancer Res. 2024 Jul 5. doi: 10.1158/1078-0432.CCR-24-0826.
    >> Share

    June 2024
  13. BOWEN MB, Melendez B, Zhang Q, Yang RK, et al
    Long-term follow-up of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer reveals relapse characterized by immune exhaustion.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0362.
    >> Share

  14. LEE HHY, Chow KL, Wong HS, Chong TY, et al
    Inhibition of aberrantly overexpressed Polo-like kinase 4 is a potential effective treatment for DNA damage repair-deficient uterine leiomyosarcoma.
    Clin Cancer Res. 2024 Jun 7. doi: 10.1158/1078-0432.CCR-23-3720.
    >> Share

  15. SANER FAM, Takahashi K, Budden T, Pandey A, et al
    Concurrent RB1 Loss and BRCA-Deficiency Predicts Enhanced Immunological Response and Long-Term Survival in Tubo-Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-3552.
    >> Share

    May 2024
  16. CORBAUX P, Freyer G, Glehen O, You B, et al
    Intraperitoneal Nivolumab After Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.
    Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-24-0507.
    >> Share

  17. HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al
    Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial.
    Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341.
    >> Share

  18. SHETH SS, Oh JE, Bellone S, Siegel ER, et al
    Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
    Clin Cancer Res. 2024;30:1768-1777.
    >> Share

  19. KHUSHMAN MM, Toboni MD, Xiu J, Manne U, et al
    Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Clin Cancer Res. 2024;30:1906-1915.
    >> Share

  20. MIZUMOTO Y, Kyo S, Kiyono T, Takakura M, et al
    Editor's Note: Activation of NF-kappaB Is a Novel Target of KRAS-induced Endometrial Carcinogenesis.
    Clin Cancer Res. 2024;30:1995.
    >> Share

    April 2024
  21. LORENTZEN GM, Laniewski P, Cui H, Mahnert ND, et al
    Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification.
    Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2934.
    >> Share

  22. SON J, Zhang Y, Lin H, Mirallas O, et al
    Clinical and genomic landscape of RAS mutations in gynecologic cancers.
    Clin Cancer Res. 2024 Apr 30. doi: 10.1158/1078-0432.CCR-23-2819.
    >> Share

  23. SIVARS L, Jylha C, Crona Guterstam Y, Zupancic M, et al
    Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3941.
    >> Share

  24. NIEF CA, Hammer PM, Wang A, Charu V, et al
    Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3158.
    >> Share

  25. YANIZ-GALENDE E, Zeng Q, Grau-Bejar JF, Klein C, et al
    Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Apr 26. doi: 10.1158/1078-0432.CCR-23-3836.
    >> Share

  26. CHAMBERS L, Haight P, Chalif J, Mehra Y, et al
    Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research.
    Clin Cancer Res. 2024 Apr 25. doi: 10.1158/1078-0432.CCR-23-2570.
    >> Share

  27. VENEZIANI AC, Sneha S, Oza AM
    Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
    Clin Cancer Res. 2024;30:1434-1437.
    >> Share

  28. GITTO SB, Whicker M, Davies G, Kumar S, et al
    A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
    Clin Cancer Res. 2024;30:1567-1581.
    >> Share

    March 2024
  29. JAMIESON A, Sobral de Barros J, Cochrane DR, Douglas JM, et al
    Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3689.
    >> Share

  30. KALOGERA E, Nevala WK, Finnes HD, Suman VJ, et al
    A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
    Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3196.
    >> Share

  31. DERMAWAN JK, Chiang S, Singer S, Jadeja B, et al
    Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
    Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-24-0148.
    >> Share

    February 2024
  32. LOU H, Cai H, Huang X, Li G, et al
    Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study.
    Clin Cancer Res. 2024 Feb 19. doi: 10.1158/1078-0432.CCR-23-3162.
    >> Share

  33. BARTLETT JMS, Xu K, Wong J, Pond G, et al
    Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial.
    Clin Cancer Res. 2024 Feb 12. doi: 10.1158/1078-0432.CCR-23-2436.
    >> Share

    January 2024
  34. TAN TJ, Sammons S, Im YH, She L, et al
    Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-2513.
    >> Share

  35. WANG Y, Situ X, Cardenas H, Siu E, et al
    Preclinical evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.
    Clin Cancer Res. 2024 Jan 17. doi: 10.1158/1078-0432.CCR-23-2368.
    >> Share

  36. LUKOVIC J, Pintilie M, Han K, Fyles AW, et al
    An immune gene expression risk score for distant metastases after radiotherapy for cervical cancer.
    Clin Cancer Res. 2024 Jan 5. doi: 10.1158/1078-0432.CCR-23-2085.
    >> Share

  37. OAKNIN A, Ghamande SA, Kasamatsu Y, Gil-Martin M, et al
    Phase 1 trial of first-line bintrafusp alfa in patients with locally advanced or persistent/recurrent/metastatic cervical cancer.
    Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-1829.
    >> Share

    December 2023
  38. TSANG ES, Gallinger S
    Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer.
    Clin Cancer Res. 2023;29:5005-5007.
    >> Share

  39. BROWN TJ, Yablonovitch A, Till JE, Yen J, et al
    The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
    Clin Cancer Res. 2023;29:5207-5216.
    >> Share

  40. WANG Y, Douville C, Chien YW, Wang BG, et al
    Aneuploidy Landscape in Precursors of Ovarian Cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-0932.
    >> Share

    November 2023
  41. DREW Y, Kim JW, Penson RT, O'Malley DM, et al
    Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naive Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2249.
    >> Share

  42. SOBERANIS PINA P, Oza AM
    Methodical Manipulation of the TME in Ovarian Cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-2365.
    >> Share

  43. DENG N, Reyes-Uribe L, Fahrmann JF, Thoman WS, et al
    Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome.
    Clin Cancer Res. 2023;29:4361-4372.
    >> Share

    October 2023
  44. PATEL SP, Othus M, Chae YK, Dennis MJ, et al
    A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia.
    Clin Cancer Res. 2023 Oct 26. doi: 10.1158/1078-0432.CCR-23-2293.
    >> Share

  45. BUCKLEY DN, Lewinger JP, Gooden G, Spillman M, et al
    OvaPrint - a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer.
    Clin Cancer Res. 2023 Oct 9. doi: 10.1158/1078-0432.CCR-23-1197.
    >> Share

    September 2023
  46. JAMIESON A, Vermij L, Kramer CJH, Jobsen JJ, et al
    Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas.
    Clin Cancer Res. 2023 Sep 29. doi: 10.1158/1078-0432.CCR-23-1397.
    >> Share

  47. LEMAN R, Muller E, Legros A, Goardon N, et al
    Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
    Clin Cancer Res. 2023 Sep 26:OF1-OF11. doi: 10.1158/1078-0432.CCR-23-0898.
    >> Share

  48. SANFILIPPO R, Sbaraglia M, Fabbroni C, Croce S, et al
    Low-grade uterine Leiomyosarcoma is highly sensitive to hormonal treatment.
    Clin Cancer Res. 2023 Sep 12. doi: 10.1158/1078-0432.CCR-23-0692.
    >> Share

  49. JANGRA R, Dhani NC
    Re-routing the GPS directing immunotherapy in endometrial cancer.
    Clin Cancer Res. 2023 Sep 12. doi: 10.1158/1078-0432.CCR-23-1953.
    >> Share

    August 2023
  50. FRIEDMAN CF, Ravichandran V, Miller K, Vanderbilt C, et al
    Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
    Clin Cancer Res. 2023 Aug 29:CCR-23-1078. doi: 10.1158/1078-0432.CCR-23-1078.
    >> Share

  51. GRISHAM RN, Vergote I, Banerjee S, Drill E, et al
    Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2023 Aug 15:CCR-23-0621. doi: 10.1158/1078-0432.CCR-23-0621.
    >> Share

  52. TAVIRA B, Iscar T, Manso L, Santaballa A, et al
    Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
    Clin Cancer Res. 2023 Aug 1:CCR-23-0771. doi: 10.1158/1078-0432.CCR-23-0771.
    >> Share

    July 2023
  53. COSTAS L, Onieva I, Pelegrina B, Marin F, et al
    Evaluation of somatic mutations in urine samples as a non-invasive method for the detection and molecular classification of endometrial cancer.
    Clin Cancer Res. 2023 Jul 13:CCR-23-0367. doi: 10.1158/1078-0432.CCR-23-0367.
    >> Share

  54. DOE-TETTEH SA, Camp SY, Reales D, Crowdis J, et al
    Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach.
    Clin Cancer Res. 2023;29:2445-2455.
    >> Share

    June 2023
  55. OAKNIN A, Pothuri B, Gilbert L, Sabatier R, et al
    Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
    Clin Cancer Res. 2023 Jun 26:CCR-22-3915. doi: 10.1158/1078-0432.CCR-22-3915.
    >> Share

  56. GARG V, Oza AM
    Assessment of Homologous Recombination Deficiency in Ovarian Cancer.
    Clin Cancer Res. 2023 Jun 22:CCR-23-0563. doi: 10.1158/1078-0432.CCR-23-0563.
    >> Share

  57. HEINZE K, Cairns ES, Thornton S, Harris B, et al
    The prognostic effect of immune cell infiltration depends on molecular subtype in Endometrioid Ovarian Carcinomas.
    Clin Cancer Res. 2023 Jun 20:CCR-22-3815. doi: 10.1158/1078-0432.CCR-22-3815.
    >> Share

  58. LHEUREUX S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, et al
    Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression.
    Clin Cancer Res. 2023 Jun 16:CCR-23-0797. doi: 10.1158/1078-0432.CCR-23-0797.
    >> Share

  59. MCDERMOTT MSJ, O'Brien NA, Hoffstrom B, Gong K, et al
    Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:2131-2143.
    >> Share

  60. CHANDARLAPATY S, Dickler MN, Perez Fidalgo JA, Villanueva-Vazquez R, et al
    An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer.
    Clin Cancer Res. 2023 Jun 1:CCR-23-0011. doi: 10.1158/1078-0432.CCR-23-0011.
    >> Share

  61. SCHWARTZ GN, Kaufman PA, Giridhar KV, Marotti JD, et al
    Alternating 17beta-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
    Clin Cancer Res. 2023 Jun 1:OF1-OF7. doi: 10.1158/1078-0432.CCR-23-0112.
    >> Share

    May 2023
  62. DILAWARI A, Shah M, Ison G, Gittleman H, et al
    FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRalpha-positive, Platinum-Resistant Ovarian Cancer.
    Clin Cancer Res. 2023 May 22:CCR-23-0991. doi: 10.1158/1078-0432.CCR-23-0991.
    >> Share

  63. GONZALEZ-OCHOA E, Oza AM
    An attempt to stretch the benefit: Re-challenge with PARP inhibitors in ovarian cancer.
    Clin Cancer Res. 2023 May 16:CCR-23-0652. doi: 10.1158/1078-0432.CCR-23-0652.
    >> Share

  64. SCHWARTZ GN, Kaufman PA, Giridhar KV, Marotti JD, et al
    Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer.
    Clin Cancer Res. 2023 May 15:CCR-23-0112. doi: 10.1158/1078-0432.CCR-23-0112.
    >> Share

  65. DORIGO O, Oza AM, Pejovic T, Ghatage P, et al
    Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial.
    Clin Cancer Res. 2023 May 1:CCR-22-2595. doi: 10.1158/1078-0432.CCR-22-2595.
    >> Share

    April 2023
  66. COMPADRE AJ, van Biljon LN, Valentine MC, Llop-Guevara A, et al
    RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-3335. doi: 10.1158/1078-0432.CCR-22-3335.
    >> Share

  67. WETHINGTON SL, Shah PD, Martin L, Tanyi JL, et al
    Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-2444. doi: 10.1158/1078-0432.CCR-22-2444.
    >> Share

  68. BLANC-DURAND F, Tang R, Pommier M, Nashvi M, et al
    Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients.
    Clin Cancer Res. 2023 Apr 17:CCR-22-3328. doi: 10.1158/1078-0432.CCR-22-3328.
    >> Share

  69. KIM YN, Shim Y, Seo J, Choi Z, et al
    Investigation of poly ADP-ribose polymerase inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer.
    Clin Cancer Res. 2023 Apr 17:CCR-22-3715. doi: 10.1158/1078-0432.CCR-22-3715.
    >> Share

  70. LIU YL, Zamarin D
    Shedding Light on PARP Inhibitor Response through Functional Imaging.
    Clin Cancer Res. 2023;29:1384-1386.
    >> Share

    March 2023
  71. YAGISHITA S, Nishikawa T, Yoshida H, Shintani D, et al
    Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy.
    Clin Cancer Res. 2023 Mar 28:CCR-22-3861. doi: 10.1158/1078-0432.CCR-22-3861.
    >> Share

  72. BATALINI F, Mina LA, Mina A
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter.
    Clin Cancer Res. 2023;29:1157.
    >> Share

  73. MARMOUSET V, Morice PM, Pages A, Leary A, et al
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response.
    Clin Cancer Res. 2023;29:1158-1159.
    >> Share

    February 2023
  74. AL-RAWI DH, Rusk N, Friedman CF
    The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer.
    Clin Cancer Res. 2023 Feb 24:CCR-23-0048. doi: 10.1158/1078-0432.CCR-23-0048.
    >> Share

  75. PIKKUSAARI S, Tumiati M, Virtanen A, Oikkonen J, et al
    Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.
    Clin Cancer Res. 2023 Feb 20:CCR-22-3156. doi: 10.1158/1078-0432.CCR-22-3156.
    >> Share

  76. MORGAN RD, Clamp AR, White DJ, Price M, et al
    Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
    Clin Cancer Res. 2023 Feb 17:CCR-22-3282. doi: 10.1158/1078-0432.CCR-22-3282.
    >> Share

  77. COLE AJ, Panesso-Gomez S, Shah JS, Ebai T, et al
    Quiescent ovarian cancer cells secrete follistatin to induce chemotherapy resistance in surrounding cells in response to chemotherapy.
    Clin Cancer Res. 2023 Feb 16:CCR-22-2254. doi: 10.1158/1078-0432.CCR-22-2254.
    >> Share

    January 2023
  78. GREEN DS, Ning F, Duemler A, Myers TG, et al
    Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
    Clin Cancer Res. 2023;29:501.
    >> Share

  79. WAINBERG ZA, Singh AS, Konecny GE, McCann KE, et al
    Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
    Clin Cancer Res. 2023;29:40-49.
    >> Share

  80. LANDEN CN, Molinero L, Hamidi H, Sehouli J, et al
    Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
    Clin Cancer Res. 2023 Jan 3:CCR-22-2032. doi: 10.1158/1078-0432.CCR-22-2032.
    >> Share

    December 2022
  81. LYNG H, Skipar K, Hompland T
    Targeted Therapy on the Screen: Do We Hit the Target?
    Clin Cancer Res. 2022;28:5233-5234.
    >> Share

  82. MARMOUSET V, Decroocq J, Garciaz S, Etienne G, et al
    Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
    Clin Cancer Res. 2022;28:5211-5220.
    >> Share

    November 2022
  83. PANTEL AR, Gitto SB, Makvandi M, Kim H, et al
    [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study.
    Clin Cancer Res. 2022 Nov 28:CCR-22-1602. doi: 10.1158/1078-0432.CCR-22-1602.
    >> Share

  84. CHOW S, Dorigo O
    Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy.
    Clin Cancer Res. 2022 Nov 16. pii: 710895. doi: 10.1158/1078-0432.CCR-22-2877.
    >> Share

  85. HILLEMANNS P, Denecke A, Woelber L, Bohmer G, et al
    A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial.
    Clin Cancer Res. 2022;28:4885-4892.
    >> Share

  86. GRANT BM, Pugh TJ, Oza AM
    Molecular monitoring in endometrial cancer - ready for prime time?
    Clin Cancer Res. 2022 Nov 10. pii: 710550. doi: 10.1158/1078-0432.CCR-22-2781.
    >> Share

    October 2022
  87. ELIA A, Saldain L, Vanzulli SI, Helguero LA, et al
    Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial.
    Clin Cancer Res. 2022 Oct 21. pii: 709943. doi: 10.1158/1078-0432.CCR-22-2060.
    >> Share

  88. GHOSH S, Mazumdar T, Xu W, Powell RT, et al
    Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers.
    Clin Cancer Res. 2022;28:4479-4493.
    >> Share

  89. VENEZIANI AC, Oza AM
    Taking the Road Less Traveled: Following Molecular Trail Markers.
    Clin Cancer Res. 2022;28:4357-4359.
    >> Share

  90. MEAGHER NS, Gorringe KL, Wakefield MJ, Bolithon A, et al
    Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.
    Clin Cancer Res. 2022 Oct 12. pii: 709665. doi: 10.1158/1078-0432.CCR-22-1206.
    >> Share

    September 2022
  91. AN J, Tang J, Li BX, Xiong H, et al
    Efficacy and Safety of the Anti-PD-L1 Monoclonal Antibody Socazolimab for Recurrent or Metastatic Cervical Cancer: A Phase I Dose-Escalation and Expansion Study.
    Clin Cancer Res. 2022 Sep 22. pii: 709354. doi: 10.1158/1078-0432.CCR-22-1280.
    >> Share

  92. GREEN DS, Ning F, Duemler A, Myers TG, et al
    Intraperitoneal monocytes and interferons as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results of a phase I clinical trial.
    Clin Cancer Res. 2022 Sep 13. pii: 709187. doi: 10.1158/1078-0432.CCR-22-1893.
    >> Share

  93. LHEUREUX S
    Multi-omics uncovering different faces of Clear Cell Ovarian Cancer.
    Clin Cancer Res. 2022 Sep 12. pii: 709169. doi: 10.1158/1078-0432.CCR-22-2365.
    >> Share

  94. BATALINI F, Gulhan DC, Mao V, Tran A, et al
    Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    Clin Cancer Res. 2022 Sep 1. pii: 708955. doi: 10.1158/1078-0432.CCR-22-0749.
    >> Share

    August 2022
  95. CONSTANTINIDOU A, Marcou Y, Toss MS, Simmons T, et al
    Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer.
    Clin Cancer Res. 2022 Aug 31. pii: 708058. doi: 10.1158/1078-0432.CCR-22-0619.
    >> Share

  96. IRAJIZAD E, Han CY, Celestino J, Wu R, et al
    A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses.
    Clin Cancer Res. 2022 Aug 29. pii: 708818. doi: 10.1158/1078-0432.CCR-22-1113.
    >> Share

  97. HAN K, Fyles A, Shek T, Croke J, et al
    A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.
    Clin Cancer Res. 2022 Aug 29. pii: 708819. doi: 10.1158/1078-0432.CCR-22-1665.
    >> Share

  98. ASHLEY CW, Selenica P, Patel J, Wu M, et al
    High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer.
    Clin Cancer Res. 2022 Aug 25. pii: 708712. doi: 10.1158/1078-0432.CCR-22-1134.
    >> Share

  99. WIMBERGER P, Gerber MJ, Pfisterer J, Erdmann K, et al
    Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an anti-angiogenic VEGF-A splice variant.
    Clin Cancer Res. 2022 Aug 24. pii: 708584. doi: 10.1158/1078-0432.CCR-22-1326.
    >> Share

  100. BANERJEE S, Michalarea V, Ang JE, Ingles Garces A, et al
    A phase I trial of CT900, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer.
    Clin Cancer Res. 2022 Aug 19. pii: 708154. doi: 10.1158/1078-0432.CCR-22-1268.
    >> Share

  101. MILLER KM, Friedman CF
    Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
    Clin Cancer Res. 2022 Aug 10. pii: 707611. doi: 10.1158/1078-0432.CCR-22-1779.
    >> Share

  102. SERRA V, Wang AT, Castroviejo-Bermejo M, Polanska UM, et al
    Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.
    Clin Cancer Res. 2022 Aug 3. pii: 707431. doi: 10.1158/1078-0432.CCR-22-0568.
    >> Share

  103. SINGER CF, Holst F, Steurer S, Burandt EC, et al
    Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
    Clin Cancer Res. 2022 Aug 3:OF1-OF9. doi: 10.1158/1078-0432.CCR-21-4328.
    >> Share

  104. LEE JM, Moore RG, Ghamande S, Park MS, et al
    Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
    Clin Cancer Res. 2022 Aug 2. pii: 707411. doi: 10.1158/1078-0432.CCR-21-1733.
    >> Share

    July 2022
  105. MANNING-GEIST BL, Liu YL, Devereaux KA, Da Cruz Paula A, et al
    Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles.
    Clin Cancer Res. 2022 Jul 18. pii: 707055. doi: 10.1158/1078-0432.CCR-22-0713.
    >> Share

  106. BOLTON KL, Chen D, Corona de la Fuente RI, Fu Z, et al
    Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes.
    Clin Cancer Res. 2022 Jul 11. pii: 706955. doi: 10.1158/1078-0432.CCR-21-3817.
    >> Share

  107. FISHER NC, Byrne RM, Leslie H, Wood C, et al
    Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data.
    Clin Cancer Res. 2022 Jul 6. pii: 706888. doi: 10.1158/1078-0432.CCR-22-1102.
    >> Share

  108. MARIN-JIMENEZ JA, Garcia-Mulero S, Matias-Guiu X, Piulats JM, et al
    Facts and hopes in immunotherapy of endometrial cancer.
    Clin Cancer Res. 2022 Jul 5. pii: 706852. doi: 10.1158/1078-0432.CCR-21-1564.
    >> Share

    June 2022
  109. NOH JJ, Cho YJ, Ryu JY, Choi JJ, et al
    Anti-cancer activity of the combination of cabozantinib and temozolomide in uterine sarcoma.
    Clin Cancer Res. 2022 Jun 21. pii: 705009. doi: 10.1158/1078-0432.CCR-22-0985.
    >> Share

  110. JOHNSON M, Dudek AZ, Sukari A, Call J, et al
    ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
    Clin Cancer Res. 2022;28:2517-2526.
    >> Share

  111. HOLLIS RL, Meynert AM, Michie CO, Rye T, et al
    Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification.
    Clin Cancer Res. 2022 Jun 13. pii: 704888. doi: 10.1158/1078-0432.CCR-22-0368.
    >> Share

  112. XU J, Fang Y, Chen K, Li S, et al
    Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer.
    Clin Cancer Res. 2022 Jun 8. pii: 704811. doi: 10.1158/1078-0432.CCR-22-0296.
    >> Share

  113. FENG J, Tang D, Wang J, Zhou Q, et al
    SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, for recurrent or metastatic cervical cancer: a clinical expansion cohort of phase 1 study.
    Clin Cancer Res. 2022 Jun 2. pii: 699316. doi: 10.1158/1078-0432.CCR-22-0346.
    >> Share

  114. BYCHKOVSKY BL, Li T, Sotelo J, Tayob N, et al
    Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    Clin Cancer Res. 2022;28:2349-2360.
    >> Share

  115. NICUM S, Blagden SP
    PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    Clin Cancer Res. 2022;28:2201-2203.
    >> Share

    May 2022
  116. ARANDA F, Eguren-Santamaria I, Bella A, Berraondo P, et al
    Revisiting Intracavitary Immunotherapy of Cancer.
    Clin Cancer Res. 2022;28:1993-1995.
    >> Share

  117. FUCIKOVA J, Hensler M, Kasikova L, Lanickova T, et al
    An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors.
    Clin Cancer Res. 2022 May 10. pii: 696491. doi: 10.1158/1078-0432.CCR-21-4413.
    >> Share

    April 2022
  118. YANG SYC, Pugh TJ, Oza AM
    Double trouble: whole genome doubling distinguishes early from late ovarian cancer.
    Clin Cancer Res. 2022 Apr 27. pii: 694785. doi: 10.1158/1078-0432.CCR-22-0336.
    >> Share

  119. MANNING-GEIST B, Gordhandas S, Liu YL, Zhou Q, et al
    MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma.
    Clin Cancer Res. 2022 Apr 20. pii: 694634. doi: 10.1158/1078-0432.CCR-21-4183.
    >> Share

  120. LIU M, Tayob N, Penter L, Sellars M, et al
    Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer.
    Clin Cancer Res. 2022 Apr 20. pii: 694633. doi: 10.1158/1078-0432.CCR-21-2834.
    >> Share

  121. CHENG Z, Mirza H, Ennis DP, Smith P, et al
    The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643.
    >> Share

  122. LIM JSJ, Wong ALA, Ow SGW, Ngoi NYL, et al
    Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694118. doi: 10.1158/1078-0432.CCR-21-4179.
    >> Share

  123. AREND RC, Scalise CB, Gordon ER, Davis AM, et al
    Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.
    Clin Cancer Res. 2022;28:1433-1445.
    >> Share

    March 2022
  124. YOSHIDA K, Yokoi A, Yamamoto T, Hayashi Y, et al
    Aberrant activation of cell cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in uterine leiomyosarcoma.
    Clin Cancer Res. 2022 Mar 18. pii: 682165. doi: 10.1158/1078-0432.CCR-22-0100.
    >> Share

  125. VAN DEN HELDER R, Steenbergen RDM, van Splunter AP, Mom CH, et al
    HPV AND DNA METHYLATION TESTING IN URINE FOR CERVICAL INTRAEPITHELIAL NEOPLASIA AND CERVICAL CANCER DETECTION.
    Clin Cancer Res. 2022 Mar 10. pii: 682143. doi: 10.1158/1078-0432.CCR-21-3710.
    >> Share

    February 2022
  126. DIGKLIA A, Coukos G, Homicsko K
    Trabectedin and Durvalumab Combination is Feasible - and Active in Relapsing Ovarian Cancer.
    Clin Cancer Res. 2022 Feb 17. pii: 681578. doi: 10.1158/1078-0432.CCR-21-4592.
    >> Share

  127. GAO Q, Zhu J, Zhao W, Huang Y, et al
    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
    Clin Cancer Res. 2022 Feb 7. pii: 1078-0432.CCR-21-3023.
    >> Share

  128. SERRITELLA AV, Shevrin D, Heath EI, Wade JL, et al
    Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-4049.
    >> Share

    January 2022
  129. ORR B, Mahdi H, Fang Y, Strange M, et al
    Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3659.
    >> Share

  130. VOUGIOUKLAKIS T, Zhu K, Vasudevaraja V, Serrano J, et al
    Integrated analysis of ovarian juvenile granulosa cell tumors reveals distinct epigenetic signatures and recurrent TERT rearrangements.
    Clin Cancer Res. 2022 Jan 14. pii: 1078-0432.CCR-21-3394.
    >> Share

  131. GARCIA-SAENZ JA, Martinez-Janez N, Cubedo R, Jerez Y, et al
    Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor.
    Clin Cancer Res. 2022 Jan 3. pii: 1078-0432.CCR-21-2652.
    >> Share

    December 2021
  132. TOULMONDE M, Brahmi M, Giraud A, Chakiba C, et al
    Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2258.
    >> Share

  133. SHARMA SK, Mack KN, Piersigilli A, Pourat J, et al
    ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-1798.
    >> Share

    November 2021
  134. WU X, Zhu J, Wang J, Lin ZQ, et al
    Pamiparib Monotherapy for Patients With Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-1186.
    >> Share

  135. VAN DER WIJNGAART H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, et al
    Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
    Clin Cancer Res. 2021;27:6106-6114.
    >> Share

    October 2021
  136. ARORA S, Narayan P, Ison G, Berman T, et al
    U.S. FDA Drug Approvals for Gynecological Malignancies - A Decade in Review.
    Clin Cancer Res. 2021 Oct 28. pii: 1078-0432.CCR-21-2599.
    >> Share

  137. MOORE KN, Chambers SK, Hamilton EP, Chen LM, et al
    Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-0158.
    >> Share

  138. TIAN L, Xu B, Teng KY, Song M, et al
    Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1248.
    >> Share

    September 2021
  139. SCHOUTEN PC, Richters LK, Vis DJ, Kommoss S, et al
    Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1673.
    >> Share

  140. DO KT, Kochupurakkal B, Kelland S, de Jonge A, et al
    Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
    Clin Cancer Res. 2021;27:4710-4716.
    >> Share

    August 2021
  141. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    >> Share

  142. WILLIAMSON CW, Zamarin D, Mayadev J
    Standardized Uptake Value Illuminates Tumor Inflammation and Treatment Response.
    Clin Cancer Res. 2021;27:4136-4138.
    >> Share

    July 2021
  143. MONDINI M, Deutsch E
    (Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?
    Clin Cancer Res. 2021;27:3815-3817.
    >> Share

    January 2021
  144. HONG B, Chapa V, Saini U, Modgil P, et al
    Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
    Clin Cancer Res. 2021;27:542-553.
    >> Share

    September 2020
  145. JIN ZH, Tsuji AB, Degardin M, Sugyo A, et al
    Radiotheranostic Agent (64)Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer.
    Clin Cancer Res. 2020 Sep 15. pii: 1078-0432.CCR-20-1205.
    >> Share

  146. JORDAN K, Sikora MJ, Slansky JE, Minic A, et al
    The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1762.
    >> Share

    August 2020
  147. DA SILVA DM, Enserro DM, Mayadev J, Skeate JG, et al
    Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929).
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-0776.
    >> Share

    July 2020
  148. MORONEY JW, Powderly J, Lieu CH, Bendell JC, et al
    Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0477.
    >> Share

  149. OZA AM, Estevez-Diz MDP, Grischke EM, Hall M, et al
    A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer.
    Clin Cancer Res. 2020 Jul 1. pii: 1078-0432.CCR-20-0219.
    >> Share

    May 2020
  150. LHEUREUX S, Oaknin A, Garg S, Bruce JP, et al
    EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Clin Cancer Res. 2020 May 22. pii: 1078-0432.CCR-19-4121.
    >> Share

  151. JI JX, Cochrane DR, Tessier-Cloutier B, Chen SY, et al
    Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type.
    Clin Cancer Res. 2020 May 14. pii: 1078-0432.CCR-19-1905.
    >> Share

  152. LAMPERT EJ, Zimmer AS, Padget MR, Cimino-Mathews A, et al
    Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    Clin Cancer Res. 2020 May 12. pii: 1078-0432.CCR-20-0056.
    >> Share

    April 2020
  153. LI J, Pan C, Boese AC, Kang J, et al
    DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-3790.
    >> Share

    March 2020
  154. YOU B, Robelin P, Tod M, Louvet C, et al
    CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.
    Clin Cancer Res. 2020 Mar 24. pii: 1078-0432.CCR-20-0054.
    >> Share

    February 2020
  155. HARRIS RS, Serebrenik AA, Argyris P, Jarvis MC, et al
    The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-2786.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016